Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.54 USD
Change Today -0.71 / -5.36%
Volume 491.1K
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

supernus pharmaceuticals inc (SUPN) Snapshot

Open
$13.14
Previous Close
$13.25
Day High
$13.14
Day Low
$12.46
52 Week High
04/24/15 - $14.07
52 Week Low
05/13/14 - $7.09
Market Cap
586.6M
Average Volume 10 Days
549.2K
EPS TTM
$0.86
Shares Outstanding
46.8M
EX-Date
--
P/E TM
14.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPERNUS PHARMACEUTICALS INC (SUPN)

supernus pharmaceuticals inc (SUPN) Related Bloomberg News

View More Bloomberg News

supernus pharmaceuticals inc (SUPN) Related Businessweek News

No Related Businessweek News Found

supernus pharmaceuticals inc (SUPN) Details

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

309 Employees
Last Reported Date: 03/12/15
Founded in 2005

supernus pharmaceuticals inc (SUPN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $485.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $317.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $342.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $314.8K
Compensation as of Fiscal Year 2014.

supernus pharmaceuticals inc (SUPN) Key Developments

Supernus Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 05, 2015

Supernus Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on May 05, 2015

Supernus Pharmaceuticals, Inc. Announces Resignation of Jones W. Bryan as Vice President of Business Development

On March 26, 2015, Jones W. Bryan, Ph.D., Vice President of Business Development, resigned from Supernus Pharmaceuticals, Inc., effective April 9, 2015, to pursue other interests.

Supernus Pharmaceuticals, Inc. Appoints Georges Gemayel to the Board of Directors

Supernus Pharmaceuticals, Inc. announced that Georges Gemayel, Ph.D., an executive with extensive experience in the pharmaceutical industry, will join the company's board of directors. Dr. Gemayel has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the U.S., Europe and the Middle East. Dr. Gemayel currently serves on the board of directors of Raptor Pharmaceuticals, a publicly-traded company, and is the chairman of the boards of OxThera, EpiTherapeutics and Orphazyme ApS. From 2008 to 2009, Dr. Gemayel was president and chief executive officer of Altus Pharmaceuticals, a publicly-traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for the company's global therapeutics, transplant, renal and biosurgery businesses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUPN:US $12.54 USD -0.71

SUPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.74 USD -1.87
Cosmo Pharmaceuticals SA SFr.158.00 CHF +0.40
Depomed Inc $23.36 USD -0.53
Durect Corp $2.29 USD -0.04
Veloxis Pharmaceuticals A/S kr0.84 DKK +0.005
View Industry Companies
 

Industry Analysis

SUPN

Industry Average

Valuation SUPN Industry Range
Price/Earnings 33.7x
Price/Sales 4.7x
Price/Book 8.0x
Price/Cash Flow 31.2x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.